D-Mannose Supplements

The 2024 trial enrolled 598 women at 99 UK primary-care centres, testing 2 g daily against placebo for six months. Its main outcome was a clinically suspected UTI prompting ambulatory-care contact, rather than exclusively culture-confirmed infection.^{See reference 1}

Among 583 participants with outcome data, this occurred in 150 of 294 taking D-mannose (51.0%) and 161 of 289 taking placebo (55.7%). The estimated difference was about five percentage points; its confidence interval ran from 13 points fewer to three points more. That did not establish a clear benefit.^{See reference 1}

The smaller percentage looks favourable, but the comparison remains compatible with no difference. It does not justify promising reliable protection in similar primary-care patients. Neither does it prove that no individual could ever benefit.^{See reference 1}

A review’s result depends on which populations, study designs, preparations and outcomes it combines. The 2026 review reported substantial heterogeneity: a technical term meaning that the studies’ results differed markedly. Its authors emphasised the negative result of the largest, strongest trial.^{See reference 4}

The 2025 review also found no clear pooled benefit and called for better trials. Combining several small or inconsistent studies cannot remove all their limitations. Read the uncertainty interval and study quality before treating a favourable-looking average as a settled answer.^{See reference 3}

D-mannose has been proposed to interfere with some bacteria attaching to the urinary tract. That mechanism helped motivate trials, but a laboratory explanation is only one step. People taking a supplement need evidence that it changes outcomes they care about, such as fewer symptomatic infections.^{See reference 2}

Early studies were small and used different comparisons and preparations. A treatment can look promising in an unblinded study and then fail to show a clear advantage against a well-matched placebo. The later evidence should change how confidently the product is described.^{See reference 2,See reference 4}

The Cochrane review found sparse reporting of adverse effects, including mild diarrhoea in some studies. Limited reports do not demonstrate that every product is safe for everyone. The 2026 review also notes gaps in longer-term evidence and differences between studied groups.^{See reference 2,See reference 4}

The amount used in a trial is a study detail, not an established effective dose or a personal recommendation. The current evidence cannot justify increasing the amount to overcome a negative trial result. Evidence from adult women cannot automatically be transferred to children, pregnancy or every urinary condition.^{See reference 3,See reference 4}

Review the full product and medicine list with a clinician or pharmacist, especially when pregnant, breastfeeding or considering a supplement for a child. General supplement safety guidance also cautions against substituting a supplement for prescribed treatment.^{See reference 5}